Document is current

Article History

Received: 16 March 2018

Accepted: 6 November 2018

First Online: 17 December 2018

Change Date: 18 December 2018

Change Type: Correction

Change Details: Supplementary Data 6 as originally posted was actually Supplementary Data 5, Supplementary Data 7 as originally posted was actually Supplementary Data 6, Supplementary Data 8 as originally posted was actually Supplementary Data 7, Supplementary Data 9 as originally posted was actually Supplementary Data 8, and Supplementary Data 5 as originally posted was actually a corrupted version of Supplementary Data 9. The error has been corrected online as of 18 December 2018.

Competing interests

: B.B.-S., J.B., C.D.P., M.J.D., T.M., A.C., M.B., F.D., A.Y., L.Y., N.C.O., K. Caldwell, J.A., T.B., M.G.H., R. Rousseau, C.V., K.J., M.S., J.F. and R.Y. are employees and shareholders of Gritstone Oncology, Inc, a company developing neoantigen immunotherapies. T.A.C. and N.A.R. are founders, shareholders, and serve on the scientific advisory board of Gritstone Oncology. B.B.-S., J.B., C.D.P., T.B., M.S., J.F. and R.Y are inventors on patents and patent applications relating to this work. T.A.C. holds equity in An2H. T.A.C. acknowledges grant funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H and Eisai. T.A.C. has served as an advisor for Bristol-Myers Squibb, AstraZeneca, Illumina, Eisai and An2H. T.A.C., N.A.R. and Memorial Sloan Kettering Cancer Center have a patent filing (PCT/US2015/062208) for the use of tumor mutation burden and HLA for prediction of immunotherapy efficacy, which is licensed to Personal Genome Diagnostics. S.N. is on speaker bureaus for Eli Lilly; Bristol-Myers Squibb; Takeda; Merck, Sharp & Dohme; Boehringer Ingelheim; AstraZeneca; and AbbVie.